Vertellus to buy Chemtrade businesses
Vertellus has signed a definitive agreement to acquire the potassium chloride, caustic pellets and vaccine adjuvant businesses of diversified US chemical firm Chemtrade. Terms were not disclosed. The transaction is expected to close during Q4, subject to regulatory approval and customary closing conditions.
The company, which is owned by Pritzker Private Capital, said that this will expand its capabilities “to manufacture and develop speciality ingredients in high-growth healthcare and pharmaceutical sectors”, notably medications for hypertension and diabetes, production of next-generation biologics and improving the effectiveness of certain vaccines.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
